Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 3

Sponsor Class

OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Plasma cell 3Other hematologic neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1Classical hematology 1

Conditions

Leukemia 12Leukemia, Lymphocytic, Chronic, B-Cell 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma 5Sarcoma 4Neuroblastoma 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myeloid, Acute 4Colonic Neoplasms 4Burkitt Lymphoma 4Waldenstrom Macroglobulinemia 3Rectal Neoplasms 3Multiple Myeloma 3Lymphoma, T-Cell, Peripheral 3Lymphoma, Mantle-Cell 3Lymphoma, Extranodal NK-T-Cell 3Kidney Neoplasms 3Immunoblastic Lymphadenopathy 3Hodgkin Disease 3Colorectal Neoplasms 3Breast Neoplasms 3Wilms Tumor 2Unspecified Adult Solid Tumor, Protocol Specific 2Squamous Cell Carcinoma of Head and Neck 2Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2

Interventions

Dexamethasone 809Bortezomib 449Lenalidomide 430Cyclophosphamide 336Melphalan 251Calcium Dobesilate 237daratumumab 218pomalidomide 202carfilzomib 181fludarabine phosphate 131Thalidomide 121fludarabine 118Peripheral Blood Stem Cell Transplantation 117Filgrastim 111ixazomib 85Mycophenolic Acid 85Granulocyte Colony-Stimulating Factor 84Busulfan 83Whole-Body Irradiation 80Tacrolimus 75dexamethasone acetate 74Cyclosporine 67isatuximab 64Prednisone 64dexamethasone 21-phosphate 63elotuzumab 60auricularum 57belantamab mafodotin 55Antilymphocyte Serum 55Etoposide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Multiple Myeloma × Blotting, Western × Clear all
NCT00900055 2022-07-05

Research Study in Healthy Volunteers of Patients With Fanconi Anemia, Myeloproliferative Disorders, or Myeloma

OHSU Knight Cancer Institute

Completed
213 enrolled
Classical hematologyMyeloidPlasma cell

Fanconi Anemia, Multiple Myeloma, Myeloproliferative Disorders, Neoplasms, Plasma Cell, Myelodysplastic-Myeloproliferative Diseases

NCT01658319 2015-08-13

Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies

Case Comprehensive Cancer Center

Phase 1 Completed
20 enrolled
DermatologicLymphoidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

NCT00618345 2011-05-16

Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Mayo Clinic

Phase 2 Completed
35 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡